Streck Enters Distribution Agreement with Dow Biomedica
By LabMedica International staff writers Posted on 31 Mar 2017 |
Streck, Inc., which develops and manufactures products for clinical and research laboratories, has entered into a distribution agreement for its cell stabilization, molecular and flow cytometry products with Dow Biomedica, a distributor of diagnostic products specializing in immunology, microbiology and QC materials.
Streck’s products for clinical and research laboratories include automated erythrocyte sedimentation rate instruments, and blood collection tubes that standardize methods for sample collection, stabilization and transportation during clinical research studies, drug discovery and diagnostic assay development. The company’s product lines also include flow cytometry, body fluids and urinalysis, as well as rapid diagnostic tools being developed for molecular diagnostics. Streck is also developing a library of diagnostics tools that will soon be available in Korea and the rest of the world.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, Dow Biomedica will be able to provide excellent local support to our Korean customers.”
“Dow Biomedica continuously pursues improving service for our customers, and our partnership with Streck will enable us to provide customers with the premium quality cell stabilization and flow cytometry products they need for their downstream applications,” said YG Shin, President and CEO of Dow Biomedica.
Streck’s products for clinical and research laboratories include automated erythrocyte sedimentation rate instruments, and blood collection tubes that standardize methods for sample collection, stabilization and transportation during clinical research studies, drug discovery and diagnostic assay development. The company’s product lines also include flow cytometry, body fluids and urinalysis, as well as rapid diagnostic tools being developed for molecular diagnostics. Streck is also developing a library of diagnostics tools that will soon be available in Korea and the rest of the world.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, Dow Biomedica will be able to provide excellent local support to our Korean customers.”
“Dow Biomedica continuously pursues improving service for our customers, and our partnership with Streck will enable us to provide customers with the premium quality cell stabilization and flow cytometry products they need for their downstream applications,” said YG Shin, President and CEO of Dow Biomedica.
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus